Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys

Cardiovascular Diabetology

Volumn 3, Issue , 2004, Pages

  Edwards, Iris J ^a   Wagner, Janice D ^a   Vogl Willis, Catherine A ^a   Litwak, Kenneth N ^b   Cefalu, William T ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Arteries; Atherosclerosis; Diabetes; Glycosaminoglycans; Hyperglycemia; Proteoglycans

Indexed keywords

AGAROSE; CHOLESTEROL; DERMATAN SULFATE; GLUCOSE; GLYCOSAMINOGLYCAN; GLYCOSYLATED HEMOGLOBIN; GUANIDINE; HEPARAN SULFATE; HEXURONIC ACID; LIPOPROTEIN; PAPAIN; PROTEOGLYCAN; STREPTOZOCIN;

ANIMAL TISSUE; ARTERY WALL; ATHEROSCLEROSIS; AUTOPSY; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DENSITOMETRY; DIABETES MELLITUS; DISEASE MODEL; DISEASE PREDISPOSITION; ENZYME ANALYSIS; GEL CHROMATOGRAPHY; HEMOGLOBIN DETERMINATION; HYPERGLYCEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MONKEY; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; STREPTOZOCIN DIABETES; THORACIC AORTA; TISSUE DISTRIBUTION;

EID: 2942543239     PISSN: 14752840     EISSN: None     Source Type: Journal    
DOI: 10.1186/1475-2840-3-6     Document Type: Review

References (54)

1. Garcia MJ, McNamara PM, Gordon T, Kannel WB: Morbidity and mortality in diabetes in the Framingham population. Diabetes 1974,23:105-111.
2. Colwell JA, Lopes-Virella M, Halushka PV: Pathogenesis of atherosclerosis in diabetes mellitus. Diabetes Care 1981,4:121-133.
3. Chait A, Bierman EL, Brunzell JD: Diabetic macroangiopathy. The Diabetes Annual/1. Edited by Alberti KGMM, Krall LP. New York: Elsevier, 1985;323-348.
4. Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 1979, 2:120-126.
5. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J (Clin Res Ed) 1983, 287:867-870.
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
7. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL: Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991, 265(5):627-631.
8. Manson JE, Colditz GA, Stamfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH: A prospective study of maturityonset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991, 151(6):1141-1147.
9. Goldbourt U, Yaari S, Medalie JH: Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees. Cardiology 1993, 82(2-3):100-121.
10. Fu CC, Chang CJ, Tseng CH, Chen MS, Kao CS, Wu TJ, Wu HP, Chuang LM, Chen CJ, Tai TY Development of macrovascular diseases in NIDDM patients in northern Taiwan. A 4-yr follow-up study. Diabetes Care 1993, 16(1):137-143.
11. Kuuisisto J, Mykkanen L, Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994, 43(8):960-967.
12. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH: Albuminuria and poor clycemic control predict mortality in NIDDM. Diabetes 1995, 44(11):1303-1309.
13. Turner RC. The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998, 21 Suppl 3:C35-38.
14. Khaw Kay-Tee, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). British Medical Journal 2001, 322:1-6.
15. Hoff HF, Bradley WA, Heideman CL, Gaubatz JW, Karagas MD, Gotto, Jr, AM: Characterization of low density lipoprotein like-particle in the human aorta from grossly normal and atherosclerotic regions. Biochimica et Biophysica Acta 1979, 573:361-374.
16. Hoff HF, Gaubatz JW: Isolation, purification, and characterization of a lipoprotein containing apo B from the human aorta. Atherosclerosis 1982, 41:273-299.
17. Srinivasan SR, Dolan P, Radhakrishnamurtrhy B, Berenson GS: Isolation of lipoprotein-acid mucopolysaccharide complexes from fatty streaks of human aortas. Atherosclerosis 1972, 16:95-104.
18. Hollander W, Paddock J, Colombo M: Lipoproteins in human atherosclerotic vessels. 1. Biochemical properties of arterial low density lipoproteins, very low density lipoproteins and high density lipoproteins. Exp Mol Path 1979, 30:144-171.
19. Galis ZS, Alavi M, Moore S: Colocalization of aortic apolipoprotein B and chondroitin sulfate in an injury model of atherosclerosis. Am J Pathol 1993, 142:1432-1438.
20. Nievelstein PFEM, Fogelman AM, Mottino G, Frank JS: Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein: a deep-etch and immunolocalization study of ultrarapidly frozen tissue. Arterioscler Thromb 1991, 11:1795-1805.
21. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J: Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
22. O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, Wight TN, Chait A Comparison of Apolipoprotein and Proteoglycan Deposits in Human Coronary Atherosclerotic Plaques. Colocalization of Biglycan With Apolipoproteins. Circulation 1998, 98:519-527.
23. Sivaram P, Obunike JC, Goldberg IJ: Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix. J Biol Chem 1995, 270 (50):9760-29765.
24. Nugent MA, Karnovsky MJ, Edelman ER: Vascular cell-derived heparin sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ Res 1993, 73:1051-1060.
25. Castellot Jr. JJ, Addonizio ML, Rosenberg R, Karnovsky MJ: Cultured Endothelial Cells Produce a Heparinlike Inhibitor of Smooth Muscle Cell Growth. J Cell Biol 1981, 90:372-379.
26. Wasty F, Alavi MZ, Moore S: Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus. Diabetologia 1993, 36:316-322.
27. Litwak KN, Cefalu WT, Wagner JD: Chronic Hyperglycemia Increases Arterial Low-Density Lipoprotein Metabolism and Atherosclerosis in Cynomolgus Monkeys. Metabolism 1998, 47(8):947-954.
28. Litwak KN, Cefalu WT, Wagner JD: Streptozotocin-induced diabetes mellitus in cynomolgus monkeys: changes in carbohydrate metabolism, skin glycation, and pancreatic islets. Lab Anim Sci. 1998, 48:172-178.
29. Edwards IJ, Wagner JD, Litwak KN, Rudel LL, Cefalu WT: Glycation of plasma low density lipoproteins increases interaction with arterial proteoglycans. Diabetes Research and Clinical Practice 1999, 46:9-18.
30. Chandrasekhar S, Esterman MA, Hoffman HA: Microdetermination of proteoglycans and glycosaminoglycans in the presence of guanidine hydrochloride. Anal Biochem 1987, 161:103-108.
31. Blumenkrantz N, Asboe-Hansen G: New method for the determination of uronic acids. Anal Biochem 1973, 54:484-489.
32. Dietrich CP, McDuffie NM, Sampiao LO: Identification of acidic mucopolysaccharides by agarose gel electrophoresis. J of Chromatog 1977, 130:299-304.
33. Carr TP, Andresen CJ, Rudel, LL: Enzymatic Determination of Triglyceride, Free Cholesterol, and Total Cholesterol in Tissue Lipid Extracts. Clin Biochem 1993, 26:39-42.
34. Stevens RL. Colombo M. Gonzales JJ, Hollander W, Schmid K: The Glycosaminoglycans of the Human Artery and their Changes in Atherosclerosis. J Clinic Investigation 1976, 58:470-481.
35. Seppo, Y-H, Sumuvuori H, Karkola K, Mottonen M, Nikkari T: Glycosaminoglycans in Normal and Atherosclerotic Human Coronary Arteries. Laboratory Investigation 1986, 54(4):402-407.
36. Tammi M, Seppala PO, Lehtonen A, Mottonen M: Connective Tissue Components in Normal and Atherosclerotic Human Coronary Arteries. Atherosclerosis 1978, 29:191-194.
37. Hollman J, Schmidt A, von Bassewitz D-B, Buddecke E: Relationship of Sulfated Glycosaminoglycans and Cholesterol Content in Normal and Arteriosclerotic Human Aorta. Arteriosclerosis 1989, 9(2):54-158.
38. Wagner WD, Salisbury BGJ: Aortic Total Glycosaminoglycan and Dermatan Sulfate Changes in Atherosclerotic Rhesus Monkeys. Laboratory Investigation 1978, 39(4):322-328.
39. Iverius P-H: The Interaction between Human Plasma lipoproteins and Connective Tissue Glycosaminoglycans. J Biol Chem 1972, 247(8):2607-2613.
40. Chang Y, Yanagishita M, Hascall VC, Wight TN: Proteoglycans Synthesized by Smooth Muscle Cells Derived from Monkey (Macaca nemestrina) Aorta. J Biol Chem 1983, 258(9):5679-5688.
41. Kinsella MG, Wight TN: Isolation and Characterization of Dermatan Sulfate Proteoglycans Synthesized by Cultured Bovine Aortic Endothelial Cells. J Biol Chem 1988, 263(35):19222-19231.
42. Edwards IJ, Xu H, Wright MJ, Wagner WD: Interleukin-1 Upregulates Decorin Production by Arterial Smooth Muscle Cells. Arterioscler Thromb 1994, 14:1032-1039.
43. Schonherr E, Jarvelainen HT, Kinsella MG, Sandell LJ, Wight TN: Platelet-Derived 'Growth Factor and Transforming Growth Factor-β 1 Differentially Affect the Synthesis of Biglycan and Decorin by Monkey Arterial Smooth Muscle Cells. Arterioscler Thromb 1993, 13:1026-1036.
44. Vijayagopal P: Enhanced synthesis and accumulation of proteoglycans in cholesterol-enriched arterial smooth muscle cells. Biochem J. 1993, 294:603-611.
45. Chang MY, Potter-Perigo S, Tsoi C, Chait A, Wight TN: Oxidized Low Density Lipoproteins Regulate Synthesis of Monkey Aortic Smooth Muscle Cell Proteoglycans That Have Enhanced Native Low Density Lipoprotein Binding Properties. J Biol Chem. 2000, 275: 4766-4773.
46. Vogl-Willis CA and Edwards IJ: High glucose-induced alterations in subendothelial matrix perlecan leads to increased monocyte binding. Arterioscler Thromb Vasc Biol. 2004, in press.
47. Vogl-Willis CA and Edwards IJ. High glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta 2004, in press.
48. Parthasarathy N, Spiro RG: Effect of diabetes on the glycosaminoglycan component of the human glomerular basement membrane. Diabetes 1982, 31(8 Pt 1):738-41.
49. Vernier RL, Steffes MW, Sisson-Ross S, and Mauer SM: Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kid Intl 1992, 41:1070-1080.
50. Castellot JJ, Hoover RL, Harper PA, Karnovsky MJ: Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial-cell proliferation. Am J Pathol 1985, 120:427-435.
51. Tamsma JT, van den Born J, Bruijn JA, Assmann KJM, Weening JJ, Berden JHM, Wieslander J, Schrama E, Hermans J, Veerkamp JH, Lemkes HHPJ, van der Woude FJ: Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994, 37: 313-320.
52. van Det NF, van den Born J, Tamsma JT, Verhagen N, Berden JHM, Bruijn J, Daha M, van der Woude FJ: Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells. Kid Intl 1996, 49:1079-1089.
53. Bollineni JS, Alluru I, Reddi AS: Heparan sulfate proteoglycan synthesis and its expression are decreased in the retina of diabetic rats. Current Eye Research 1997, 16(2):127-30.
54. Ebara T, Conde K, Kako Y, Liu Y, Xu Y, Ramakrishnan R, Goldberg IJ, Shachter NS: Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 2000, 105:1807-1818.